Authors: Van de Putte, LBA Vischer, TL

Citation: Lba. Van De Putte et Tl. Vischer, EULAR and its journal, ANN RHEUM D, 60(6), 2001, pp. 545-545

Authors: van der Heijde, DMFM Van Riel, PLCM Nuver-Zwart, IH Van de Putte, LBA

Citation: Dmfm. Van Der Heijde et al., Alternative methods for analysis of radiographic damage in a randomized, double blind, parallel group clinical trial comparing hydroxychloroquine andsulfasalazine, J RHEUMATOL, 27(2), 2000, pp. 535-538

Authors: Crofford, LJ Lipsky, PE Brooks, P Abramson, SB Simon, LS Van de Putte, LBA

Citation: Lj. Crofford et al., Basic biology and clinical application of specific cyclooxygenase-2 inhibitors, ARTH RHEUM, 43(1), 2000, pp. 4-13

Authors: Doherty, M Van de Putte, LBA

Citation: M. Doherty et Lba. Van De Putte, COPE guidelines on good publication practice, ANN RHEUM D, 59(6), 2000, pp. 403-404

Authors: Furst, DE Breedveld, FC Burmester, GR Crofford, JJ Emery, P Feldmann, M Kalden, JR Kavanaugh, AF Keystone, EC Klareskog, LG Lipsky, PE Maini, RN Russell, AS Scott, DL Smolen, JS Van de Putte, LBA Visher, TL Weisman, MH

Citation: De. Furst et al., Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000), ANN RHEUM D, 59, 2000, pp. 1-2

Authors: de Visser, E Veth, RPH Pruszczynski, M Wobbes, T Van de Putte, LBA

Citation: E. De Visser et al., Diffuse and localized pigmented villonodular synovitis: evaluation of treatment of 38 patients, ARCH ORTHOP, 119(7-8), 1999, pp. 401-404